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Renal cell carcinoma (RCC) is the most common malignancy of the kidney and has a poor prognosis due to its late presentation and
resistance to current anticancer drugs. One mechanism of drug resistance, which is potentially amenable to therapeutic intervention,
is based on studies in our laboratory. CYP1B1 is a cytochrome P450 enzyme overexpressed in a variety of malignant tumours. Our
studies are now elucidating a functional role for CYP1B1 in drug resistance. Cytochrome P450 reductase (P450R) is required for
optimal metabolic activity of CYP1B1. Both CYP1B1 and P450R can catalyse the biotransformation of anticancer drugs at the site of
the tumour. In this investigation, we determined the expression of CYP1B1 and P450R in samples of normal kidney and RCC (11
paired normal and tumour and a further 15 tumour samples). The O-deethylation of ethoxyresorufin to resorufin was used to
measure CYP1B1 activity in RCC. Cytochrome P450 reductase activity was determined by following the reduction of cytochrome c
at 550nm. The key finding of this study was the presence of active CYP1B1 in 70% of RCC. Coincubation with the CYP1B1 inhibitor
alpha-naphthoflavone (10nM) inhibited this activity. No corresponding CYP1B1 activity was detected in any of the normal tissue
examined (n¼11). Measurable levels of active P450R were determined in all normal (n¼11) and tumour samples (n¼26). The
presence of detectable CYP1B1, which is capable of metabolising anticancer drugs in tumour cells, highlights a novel target for
therapeutic intervention.
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Renal cell carcinoma (RCC) is the most common malignancy
of the kidney accounting for 85% of all tumours of the kidney
(Gnarra et al, 1995). Currently, there are approximately 550
new cases of RCC diagnosed in Scotland annually with 320 deaths
from this disease in the same time period. Unfortunately, RCC is
curable only in patients presenting with resectable early-stage
disease.
The 5-year survival of patients with kidney tumours is only 43%
(ISD, 2004) and this poor prognosis is associated with late
presentation and poor response to standard anticancer drugs.
Moreover, the median survival of patients presenting with locally
advanced or metastatic disease is less than 1 year (Lineham et al,
1997). Although RCC is a highly vascular tumour and extracellular
drug delivery is probably high (Yagoda et al, 1995), chemotherapy
is largely ineffective, and response rates to cytotoxic therapy are
only 5–15% (Chapman and Goldstein, 1995). Indeed, the response
of RCC to the alkylating agents (nitrosoureas, melphalan,
cyclophosphamide and ifosphamide) is very low (Gattinoni et al,
2003). Docetaxel, vinblastine and the 50-fluoropyrimidines have all
been highlighted as effective single agents for metastatic disease,
but the response rate is still only 20% (Gattinoni et al, 2003).
Resistance of RCC to anticancer drugs is considered to be due in
part to the activity of the superfamily of drug efflux pumps, which
are responsible for ‘classical’ multidrug resistance; p-glycoprotein
(also known as MDR1 (multidrug resistance) in human beings)
was the first of this superfamily to be identified. Several treatments
including agents that alter MDR (acrivastine, nifedipine, cyclos-
porin A and other derivatives such as PSC833, quinidine and
verapamil) and immunotherapy (using interleukin 2 and inter-
feron a) have been proposed as prospective new therapies for RCC;
however, the results have been disappointing (Gattinoni et al,
2003). Indeed, cancers of the kidney are considered to be among
the most unresponsive to treatment and intrinsically drug resistant
of all human cancers (Yagoda et al, 1995), and RCC remains fatal
in nearly 80% of patients.
One mechanism of drug resistance, which is potentially
amenable to therapeutic intervention, is based on studies in our
laboratory. CYP1B1 is a cytochrome P450 xenobiotic metabolising
enzyme, which is central to the oxidative metabolism of a wide
variety of endogenous and exogenous compounds. In contrast, to
other cytochrome P450 enzymes, CYP1B1 is not expressed in
human liver (Murray et al, 1997; Edwards et al, 1998), but
demonstrates enhanced expression of immunoreactive protein in a
wide range of histologically diverse tumours including kidney,
ovarian, breast and colon tumours (Murray et al, 1997; McFadyen
et al, 1999, 2001a; Gibson et al, 2003). Our previous in vitro studies
have shown that CYP1B1 is specifically localised to tumour cells,
with no concomitant expression in normal tissue (Murray et al,
1997; McFadyen et al, 1999, 2001a).
Several P450’s have an established role in the metabolic
biotransformation of a wide variety of substrates including a
number of procarcinogens and several anticancer drugs (Gut et al,
2000; Kajita et al, 2000; Fujita and Kamataki 2001; Stiborova et al,
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y2001; Yamazaki et al, 2001; Lewis et al, 2003; Schwarz and Roots,
2003). Metabolic activation of procarcinogens and promutagens
can result in the accumulation of damaging DNA adducts; Shimada
and co-workers have shown CYP1B1 bioactivation of a diverse
range of these compounds including carcinogenic polycyclic and
nitro aromatic hydrocarbons and arylamines (Shimada et al, 1996,
1997).
Our in vitro studies have identified several anticancer drugs
(docetaxel, paclitaxel, mitoxantrone and flutamide) as substrates
for CYP1B1 (Rochat et al, 2001). Furthermore, we have shown that
the presence of CYP1B1 reduces the efficacy of docetaxel. Indeed, a
recent study has confirmed that CYP1B1 interacts with docetaxel
and reduces its cytotoxicity (Bournique and Lemarie, 2002).
We have previously highlighted the use of CYP1 inhibitors in
modulating the cytotoxic profile of a range of structurally diverse
anticancer drugs with CYP1B1 (McFadyen et al, 2001b; Rochat
et al, 2001; McFadyen et al, 2004). Chang and co-workers recently
demonstrated that the stilbene trans-resveratrol inhibited the
catalytic activity of CYP1B1 (Chang et al, 2000).
An inherent problem in determining CYP1B1 activity in tumour
tissue is that there are no truly specific assays to distinguish
between CYP1A1, CYP1A2 and CYP1B1 activity, which show close
homology with one another and overlapping substrate specificity.
However, the CYP1 inhibitor alpha-naphthoflavone has been
shown to be a suitable inhibitor to distinguish between CYP1A1
and CYP1B1 activity, and at low concentration, that is, 10nM
alpha-naphthoflavone inhibits CYP1B1 activity by 80% and
CYP1A1 activity by only 20% (Shimada et al, 1998). CYP1A2 is
constitutively expressed in the liver and is not found in
extrahepatic tissues. In this study, we used alpha-naphthoflavone
in conjunction with the O-deethylation of ethoxyresorufin, a model
substrate for the CYP1 family of enzymes to determine CYP1B1
activity.
The ability to inhibit CYP1B1 activation may have important
clinical implications both in reducing drug resistance by increas-
ing the efficacy of anticancer drugs and preventing procarcinogen
activation.
Cytochrome P450 enzymes require the presence of the micro-
somal flavoprotein cytochrome P450 reductase (P450R) for
optimal metabolic activity (Lu and Coon 1968; Lu et al, 1969).
The main function of this enzyme is the transfer of electrons from
NADPH via FAD and FMN cofactors to cytochrome P450 enzymes
(Vermilion et al, 1981). Cytochrome P450 reductase in conjunction
with the cytochrome P450 enzymes is central to the oxidative
metabolism of a wide range of anticancer drugs.
Therefore, to have a fuller understanding of the importance of
CYP1B1 as a therapeutic target in tumours, it is important to
determine the level of active CYP1B1 and P450R.
MATERIALS AND METHODS
Tissue
Samples of 11 paired normal kidney and kidney tumour and 15
additional kidney tumours submitted to the Department of
Pathology, University of Aberdeen for diagnosis over a 4-year
period were used in this study. The samples collected in this study
were consecutive cases of RCC and no special case selection was
made. None of the patients had received chemotherapy prior to
surgery. All the tumours were primary renal cell cancers and
histological classification of the tumours performed according to
the current criteria (Kovacs et al, 1997) showed 23 clear-cell
carcinomas, two chromophobe carcinomas and one papillary
carcinoma. The clinicopathological data for each patient are
summarised in Table 1. Samples of tumour and normal kidney
were dissected from the individual nephrectomy specimens.
Connective, haemorrhagic and necrotic tissue and fat were
removed from the individual specimens and samples of tumour
were taken from areas of viable tumour (confirmed by histological
examination of haematoxylin- and eosin-stained sections). Corre-
sponding samples of normal kidney were taken at least 5cm from
the tumour and confirmed by histological examination to be
composed of normal kidney with no contamination by tumour
cells. The dissected samples were then stored at  701C prior to
use, we have previously shown that this method of sampling has no
adverse effect on either protein (Murray et al, 1999) or RNA
(Cheung et al, 1999) analysis. Ethical approval for this project was
obtained from Grampian research ethics committee.
Preparation of microsomes
Frozen samples of normal kidney and RCCs were thawed on ice in
0.01 M.Tris-HCl pH 7.4 containing 1.15% potassium chloride. Once
thawed, the normal and tumour tissue were homogenised in 0.01 M
Tris-HCl containing 0.25 M sucrose and 15% glycerol using a
Polytron PT3000 Homogeniser (Kinematica AG, Switzerland).
Homogenates were centrifuged at 15000g for 20min at 41C using
a Centrikon T-124 centrifuge (Kontron Instruments, Cumber-
nauld, UK). The resultant supernatants were then centrifuged at
180000g (44000r.p.m.) for 1h at 41C using a Centrikon T-1160
centrifuge (Kontron Instruments). The pellet obtained after
centrifugation was resuspended in 0.1 M Tris-HCl, containing
15% glycerol and 1mM EDTA, and centrifuged again at 180000g
(44000r.p.m.) for 1h at 41C. A final pellet was obtained and
resuspended in 0.1 M Tris-HCl containing 15% glycerol and 1mM
EDTA. The resultant microsomes were stored at  751C prior to
use. Protein concentrations for each sample of microsomes were
determined using the Bradford method (Bradford, 1976).
Validation of O-deethylation of ethoxyresorufin assay for
determining CYP1B1 activity
The dealkylation of the alkoxyphenazone compound ethoxyresor-
ufin, a model substrate for the CYP1 family of P450 enzymes, was
used as a probe for CYP1B1 activity in this study.
To validate this assay as a measure of CYP1B1 activity, the
production of resorufin from the O-deethylation of ethoxyresor-
ufin by both CYP1B1 and CYP1A1 was measured. Microsomes
prepared from human lymphoblastoid cells, that contained
either expressed human CYP1A1 or CYP1B1, were obtained from
Gentest (Gentest Corporation, Cambridge Bioscience Ltd, Cam-
bridge, UK) and used in these experiments. Serial concentrations
of the CYP1 inhibitor alpha-naphthoflavone were included at
the following concentrations 0, 0.1, 0.5, 5, 10, 50 and 100nM.
Briefly, each 2ml incubation contained, either CYP1A1 (1pmol)
or CYP1B1 (5pmol) microsomes, 100mM Tris-HCl pH 7.4
incubated in 2ml reaction volume of Tris buffer containing
NADPH-regenerating system (1.3mM NADP
þ, 3.3mM glucose-6-
Table 1 Clinicopathological information of patients with RCC
Age (median and range) 63 years (35–96 years)
TNM stage of renal cell carcinoma
1 6/26 (23%)
2 10/26 (38.5%)
3 10/26 (38.5%)
Histological subtype
Clear-cell carcinoma 23/26 (88%)
Chromophobe 2/26 (8%)
Papillary 1/26 (4%)
RCC¼renal cell carcinoma.
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yphosphate, 0.4Uml
 1 glucose-6-phosphate dehydrogenase, 3.3mM
magnesium chloride) for 10min at 371C prior to the addition of
ethoxyresorufin (5mM final concentration) with or without the
addition of alpha-naphthoflavone. The production of resorufin was
measured by scanning spectrophotometer at the following
wavelengths: excitation 530nm and emission 585nm. Readings
were taken immediately following the addition of ethoxyresorufin
continuously over a 40min time period. The activity was calculated
from the linear portion of the graph against a known resorufin
standard (100pM).
Efficiency of CYP1B1 O-deethylation of ethoxyresorufin
To evaluate the optimal conditions and efficiency of the reaction,
we determined the Km (substrate concentration at half the
maximum velocity) of the reaction. This was performed using
serial substrate concentrations, that is, ethoxyresorufin was added
at the following final concentrations 0.1, 0.25, 0.5, 1, 2.5, 3.75, 5,
7.5, 10 and 12.5mM.
CYP1B1 activity: O-deethylation of ethoxyresorufin
The production of resorufin from the O-deethylation of
ethoxyresorufin was determined by a modified continuous
spectrofluorimetric assay based on the method of Burke and
Mayer (1974). Briefly, each 2ml incubation contained 100mM
Tris-HCl pH 7.4, NADPH-regenerating system and the microsomal
fraction of tumour samples (1mg protein); this mixture was
incubated with or without the addition of 10nM alpha-naphtho-
flavone for 10min at 371C prior to the addition of ethoxyresorufin
(1mM final concentration). The production of resorufin was
measured by scanning spectrophotometer at the following
wavelengths: excitation 530nm and emission 585nm. Readings
were taken over a 40-min period immediately following the
addition of EROD. The activity was calculated from the linear
portion of graph against a known resorufin standard (100pM).
To take account of day-to-day variation of the assay system,
CYP1A1 and CYP1B1 microsomes were included in all assays as
positive controls.
P450R activity
As the reduction of P450R is relatively difficult to measure directly,
a simplified determination of enzyme activity is widely used
utilising exogenous cytochrome c (oxidised, ferric form) as an
artificial electron acceptor. Accordingly, the reduction of cyto-
chrome c by NADPH–cytochrome c (P450) reductase mirrors the
reduction P450R. The principles of this are that the reduced
(ferrous) form has a characteristic absorption band at 550nm,
which is absent in the oxidised (ferric) form of cytochrome c.
Therefore, the enzyme activity can be conveniently assayed by
measuring the increase in absorbance at 550nm.
Briefly, each 2ml incubation contained 1.3mM NADP
þ,
3.3mM glucose-6-phosphate, 0.4Uml
 1 glucose-6-phosphate
dehydrogenase, 3.3mM magnesium chloride and 1mgml
 1 cyto-
chrome c in 0.1 M Tris-HCl (pH7.4); this mixture was incubated
at 371C prior to the addition of 100mg of microsomal protein.
As the tissue samples had a high turbidity, a split-beam spectro-
photometer comparing a sample cuvette with a reference cuvette,
which contained no regenerating system, was used to control for
sample turbidity.
Readings were taken continuously following the addition of the
microsomal protein over a 40min time period. The change in
absorbance was calculated automatically as a function of time for
the linear period of the reaction. An extinction coefficient for
reduced (ferrous) cytochrome c at 550nm of 19.6mM
 1cm
 1 was
used to calculate the reductase activity.
Statistical analysis
Statistical analysis was performed using both SigmaStat 2.03 for
Windows 2000t and SPSS version 11.5 for Windows 2000t.
Data analysis: coefficient of variation (CV)
All assays were performed in triplicate. The mean and standard
deviation were calculated for each of the samples, which were then
further analysed to determine the CV. Based on our experience
with the assays, a CV of 10% was accepted as the maximum
variation allowed under the conditions used, any sample out with
this value was discarded and repeated.
RESULTS
Validation of O-deethylation of ethoxyresorufin assay for
determining CYP1B1 activity
Determination of CYP1B1 activity was accomplished by measuring
resorufin production from the O-deethylation of ethoxyresorufin.
However, as ethoxyresorufin is also a substrate for CYP1A1 we
modified our assay system to distinguish between CYP1A1 and
CYP1B1 activities in tumour tissue, by performing the reaction
with low concentrations (10nM) of alpha-naphthoflavone, which
markedly inhibited CYP1B1 activity by 80% and inhibited CYP1A1
to a much lesser (o20%) extent (Figure 1).
Efficiency of CYP1B1 O-deethylation of ethoxyresorufin
The ethoxyresorufin activity of the lymphoblastoid expressed
CYP1B1 was determined at various concentrations of substrate.
The Km of the reaction was determined as 0.8mM (Figure 2).
CYP1B1 activity: O-deethylation of ethoxyresorufin
Determination of CYP1B1 activity was accomplished by measuring
resorufin production from the O-deethylation of ethoxyresorufin
in the presence or absence of 10nM alpha-naphthoflavone. EROD
Figure 1 Graphs illustrating the percentage of CYP1 activity demon-
strating the difference in CYP1B1 and CYP1A1 activity (production of
resorufin from the O-deethylation of ethoxyresorufin) following the
addition of alphanaphthoflavone (0, 0.1, 0.5, 5, 10, 50 and 100nM final
concentration). All assays were performed in triplicate with CYP1A1
(1pmol) and CYP1B1 (5pmol) containing microsomes prepared from
either CYP1A1- or CYP1B1-expressing human lymphoblastoid cells,
respectively.
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(n¼19/23) (65–992fmolminmg
 1 of microsomal protein) with
similar levels of CYP1B1 activity also demonstrated in the
chromophobe (n¼2) and papillary renal carcinomas (n¼1).
Coincubation with the CYP1B1 inhibitor alpha-naphthoflavone at
10nM partially inhibited this activity by greater than 20% in 16 out
of the 19 (70%) RCCs demonstrating the O-deethylation of
ethoxyresorufin (Figure 3). No production of resorufin (CYP1B1
activity) was detectable in any of the normal tissue samples
(Figure 3). The limit of sensitivity of this assay was
20fmolminmg
 1 of microsomal protein.
Cytochrome P450 reductase
All the normal tissue and tumour samples demonstrated P450R
activity with considerable variability in expression between the two
groups. A higher level of P450R was demonstrated in the normal
kidney (mean¼1024 and range¼525–2097 P450R activity
pmolminmg
 1 microsomal protein) compared to the kidney
tumours (mean¼308 and range¼34–2969 P450R activity
pmolminmg
 1 microsomal protein) Figure 4. This difference in
P450R activity between the normal kidney and RCC was shown to
be significant in the 11 paired samples by a paired t-test (t¼4.614,
degrees of freedom (df)¼10, P¼0.001). No relationship was
found between P450R activity histological diagnosis and stage of
the tumours (w
2¼2.889, with 4df, P¼0.577). The limit of
0
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Figure 2 Efficiency of CYP1B1 activity demonstrated by (A) Michaelis–Menten and (B) Linneweaver–Burke plots illustrating the Km and Vmax for
CYP1B1 O-deethylation of ethoxyresorufin.
Normal kidney Renal cell carcinoma
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Figure 3 Distribution of CYP1B1 activity in normal kidney and RCC.
CYP1B1 activity according to the change in resorufin production
DR¼Rni Ri (DR is the change in CYP1B1 activity, Rni is the resorufin
production in the absence of the inhibitor alpha-naphthoflavone and Ri is
the resorufin production in the presence of 10nM alpha-naphthoflavone.
Boxes delimit the first and third quartiles with the median inside. Circle (J)
represents outlier, defined as individual values 1.5–3 times greater than the
interquartile range. No box is present for the normal kidney due to the
absence of CYP1B1 activity.
Normal kidney Renal cell carcinoma
0.00
1000.00
2000.00
3000.00 ∆
Figure 4 Distribution of P450R activity in normal kidney and RCC,
according to cytochrome c production. Boxes delimit the first and third
quartiles, with the median inside and bars representing the range of values
that fall within 1.5-fold the interquartile range. Circle (J) represents
outlier, defined as individual values 1.5–3 times greater than the
interquartile range. Triangle (D) represents extreme, defined as individual
values greater than three times the interquartile range.
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 1
microsomal protein.
DISCUSSION
CYP1B1 has been identified in a wide range of histologically
distinct human neoplasms. Our in vitro studies have shown
that this P450 is overexpressed in tumours and is specifically
expressed in tumour cells (Murray et al, 1997; McFadyen et al,
1999; Murray, 2000). We have recently shown that CYP1B1
demonstrates a similarly high level of expression in metastatic
disease (McFadyen et al, 2001a). Moreover, the presence of
CYP1B1 protein is undetectable in normal liver (Murray et al,
1997; Edwards et al, 1998; Chang et al, 2003). In this study, by
the use of the CYP1 inhibitor alpha-naphthoflavone at a low
concentration (10nM), which distinguishes between CYP1A1
and CYP1B1, we showed measurable CYP1B1 activity in RCC.
We found CYP1B1 activity in primary RCC in 16 out of 19
samples (70%) with no detectable CYP1B1 observed in the normal
kidney. However, we were unable to inhibit all the P450 activity
observed in the RCCs at the concentration of alpha-naphtho-
flavone used in this study. Therefore, the presence of other
metabolically active P450 enzymes such as CYP1A1 and CYP3A,
which also catalyse the O-deethylation of ethoxyresorufin must be
considered. This investigation has provided evidence for CYP1B1
activity in RCCs and the presence of other metabolically active
P450 enzymes in RCCs.
Cytochrome P450 reductase is an essential component of the
cytochrome P450 monoxygenase system, which catalyses the
transfer of electrons from NADPH to P450 enzymes (Djordjevic
et al, 1995). P450R is also involved in the bioreductive metabolism
of a number of anticancer drugs including tirapazamine (Patterson
et al, 1995). In this study, P450R was expressed in both normal and
tumour tissue with some variation in expression observed in both
groups. Lo ´pez de Cerain et al (1999) observed similar levels of
P450R expression in normal lung and lung tumours. In this study,
a higher level of P450R was observed in the normal tissue
compared to the RCC. Henderson et al (2003) have recently
reported an almost five-fold increase in P450 levels in P450R
knockout mice, although the mechanism of action is unknown.
Little is known about the regulatory mechanisms governing P450
enzymes in tumour tissue, and much remains to be elucidated
about both the function and the mechanisms regulating their
expression.
The presence of metabolically active CYP1B1, which is over-
expressed in tumours and which is capable of metabolising
anticancer drugs within the tumour cells offers tremendous
opportunities for the development of novel prodrugs activated
by CYP1B1 only in the tumour cells (Murray et al, 2001; Patterson
and Murray, 2002). Indeed, several classes of prodrug, designed to
be activated selectively by CYP1B1 at the site of the tumour, are
currently in preclinical evaluation. One of the most promising of
these compounds resveratrol was recently shown to be metabolised
by CYP1B1 to the anticancer agent piceatannol (Potter et al, 2002).
In addition, the ability to inhibit CYP1B1 activity highlights
a target for the development of an inhibitor, which would increase
the efficacy of currently available cytotoxic agents at the site of
the tumour.
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